Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process.
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...